Paediatric indication for Xalatan

Pfizer has received a licence extension for Xalatan 0.005% (latanoprost) permitting use of the eye drops in children with elevated intraocular pressure or glaucoma. Dosing is the same as for adults.

Latanoprost is the first prostaglandin analogue to complete safety and efficacy trials in the paediatric population and to be indicated for use in patients under 18 years old in the UK. No data are available for preterm infants (<36 weeks gestational age) and data are very limited in children under 1 year.

View Xalatan drug record

Further information: Pfizer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in